In HFrEF and CAD, ACE inhibitors and ARBs are essential in managing HFrEF by targeting the renin–angiotensin–aldosterone system, reducing mortality, myocardial remodeling, and hospitalizations in CAD patients. The gene discussed is REN; the disease is coronary artery disorder.